s General Hospital Neurological Clinical Research Institute announced they are collaborating with GlaxoSmithKline (GSK) on a clinical trial to evaluate the potential of an anti-epileptic drug in ALS patients. In May 2015, The University of North Carolina at Chapel Hill and GSK announced the creation of the dedicated HIV Cure center and a jointly owned new company that would focus on discovering a cure for HIV/AIDS. In June 2015, GlaxoSmithKline (UK) has announced the launch of an independent non-profit research institute - the Altius Institute for Biomedical Sciences - based in Seattle, Washington. GSK signed a 10-year research agreement with Altius, whereby the firm would contribute more than USD 95 million in the first five years to help fund research activities that are also anticipated to receive funding from public and other sources. In July 2015, Medical Research Council (MRC) and GlaxoSmithKline (GSK) and five leading UK universities collaborate to crack difficult disease areas. MRC and GSK are to collaborate on a unique open innovation research initiative aiming to improve scientists' understanding of inflammatory diseases that present a serious burden to patients. In September 2015, Siemens announced it has signed a global strategic partnership with GlaxoSmithKline to become a strategic partner of GSK in manufacturing automation. Siemens will also become the preferred automation provider for GSK production and R&D sites globally, including vaccines. In October 2015, GSK and the Université de Sherbrooke announced the signing of a collaboration agreement to develop a new medicine that could potentially lead to new treatment options for patients with iron overload disorders (IOD) such as beta-thalassemia or hereditary hemochromatosis. In October 2015, Pfizer Inc. announced a multi-year collaboration with GSK on the development of a next-generation equipment design, building upon Pfizer’s existing portable, continuous, miniature and modular (PCMM) prototype for oral solid dose (OSD) pharmaceutical development and manufacturing. In November 2015, Shionogi & Co. announced that it has terminated the joint development of new antibiotics with GlaxoSmithKline PLC. The two companies will independently develop and commercialize such antibiotics. On December 1, 2015, Propeller Health announced a development agreement and R&D collaboration with GSK for its Ellipta inhaler, the pharmaceutical company's innovative, patented, dry powder inhaler. Under the terms of this non-exclusive agreement, the first between the two companies, Propeller Health will develop and manufacture a custom sensor for the Ellipta inhaler for use in certain GSK clinical studies in asthma and COPD. In December 2015, Idera Pharmaceuticals, Inc. has entered into a worldwide collaboration and license agreement with GSK to research, develop and commercialize selected molecules from Idera's third generation antisense platform for the treatment of selected targets in renal disease. In February 2016, Valneva SE announced that it has signed a new R&D collaboration agreement with GlaxoSmithKline for the development of EB66®-based Influenza vaccines. History GlaxoSmithKline plc was founded in 1935.
glaxosmithkline plc (GS7:Xetra)
980 Great West Road
Brentford, TW8 9GS
Phone: 44 20 8047 5000
|3M Co||$153.96 USD||+3.29|
|Bristol-Myers Squibb Co||$60.20 USD||+0.68|
|Medtronic PLC||$73.40 USD||+0.78|
|Novo Nordisk A/S||kr321.20 DKK||+3.20|
|View Industry Companies|
Sponsored Financial Commentaries
To contact GLAXOSMITHKLINE PLC, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.